Nuclear Medicine Communications最新文献

{"title":"Quantitative analysis of the relation between urinary iodine concentration and thyroid iodine uptake rate in newly diagnosed Graves' disease: a single-center retrospective study.","authors":"Wei Qu, Bing Wang, Tianyuan Hu, Long Zheng","doi":"10.1097/MNM.0000000000002051","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002051","url":null,"abstract":"<p><strong>Objective: </strong>The efficacy of radioactive iodine-131 (RAI) therapy for Graves' disease (GD) depends on thyroid iodine uptake, which may be influenced by iodine status. This study investigated the relationship between urinary iodine concentration (UIC) and RAI uptake (RAIU) in newly diagnosed, drug-naive GD patients.</p><p><strong>Methods: </strong>We retrospectively analyzed 248 patients with GD who underwent RAIU measurements at 2, 4, and 24 h after iodine-131 administration. UIC was measured using arsenic-cerium catalytic spectrophotometry. RAIU was calculated using standardized counts, and correlations with UIC were assessed via Pearson's correlation and linear regression. Group comparisons were performed with analysis of variance or Mann-Whitney U tests.</p><p><strong>Results: </strong>The median UIC was 222.52 μg/L. Female patients had higher RAIU than males at all time points. RAIU declined with age (P < 0.05). Elevated UIC showed significant inverse correlations with RAIU-2 h (r = -0.15, P = 0.015), RAIU-4 h (r = -0.21, P = 0.001), and RAIU-24 h (r = -0.28, P < 0.001). Notably, patients with UIC > 300 μg/L demonstrated a 15-20% reduction in RAIU compared with those with normal UIC (100-300 μg/L). Gender, age, and some renal function indices showed no significant correlation with UIC.</p><p><strong>Conclusion: </strong>This retrospective study adds some quantitative evidence on the relationship between UIC and RAIU in patients with newly diagnosed GD, further demonstrating that higher UIC values are associated with suppressed RAIU. These findings highlight the importance of pre-therapeutic UIC screening to optimize RAI dosing and planning, particularly in regions with variable dietary iodine intake.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145086855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of different response evaluation criteria in interim PET/computed tomography for diffuse large B-cell lymphoma: is Δtotal metabolic tumor volume a worthwhile measure?","authors":"Gündüzalp B Babacan, Müge Öner Tamam, Naciye Demirel, İlknur Mansuroğlu, Hülya Bilgi","doi":"10.1097/MNM.0000000000002047","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002047","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the most reliable predictors of progression-free survival (PFS) and overall survival (OS) among six different response criteria during interim PET (I-PET)/computed tomography (CT), including the change in total metabolic tumor volume (ΔTMTV) in patients with diffuse large B-cell lymphoma (DLBCL).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on patients with DLBCL who underwent baseline PET/CT and I-PET after 3-4 cycles of chemoimmunotherapy. Various response criteria were assessed, including Lugano, response evaluation criteria in lymphoma (RECIL), change in maximum standardized uptake value (ΔSUVmax), Peking, quantitative PET, and the novel ΔTMTV. Survival outcomes were obtained using Kaplan-Meier survival analysis and Cox proportional-hazards regression models and compared with Harrell's C-index for predictive accuracy.</p><p><strong>Results: </strong>One hundred and two patients enrolled. The median PFS was 58 months, and the median OS was 63.5 months. ΔSUVmax (cut-off: 66%) had the highest predictive accuracy for both PFS and OS (C-index: 0.689, 0.686; P < 0.001). ΔTMTV (cut-off: 85.69%) was significantly associated with survival (P = 0.003 for PFS, P = 0.005 for OS) but did not outperform other response criteria. RECIL showed better survival prediction when minor responders were categorized as stable disease rather than partial response. A high baseline TMTV (>126.8 cm³) was correlated with lower survival, as indicated by PFS (P = 0.004) and OS (P = 0.019).</p><p><strong>Conclusion: </strong>Interim PET/CT response evaluation using ΔSUVmax66 is the most reliable predictor of survival in DLBCL. ΔTMTV has potential but requires improvement to enhance its prognostic accuracy. Future studies should explore refined segmentation methods to enhance metabolic tumor volume assessment in clinical practice.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccine-associated reactive axillary lymph nodes on FDG PET/CT: a systematic review and meta-analysis.","authors":"Mehmet Emin Adin, Daniel Nguyen, Clifford Shin, Darko Pucar","doi":"10.1097/MNM.0000000000002041","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002041","url":null,"abstract":"<p><strong>Purpose: </strong>COVID-19 vaccine-induced reactive axillary lymph nodes (RAL) on fluorodeoxyglucose (FDG) PET/computed tomography (CT) imaging can mimic malignant lymphadenopathy, leading to diagnostic errors. Reported RAL prevalence varies widely in the literature, and factors contributing to its development remain poorly understood. This meta-analysis aims to evaluate vaccine-induced RAL observed on FDG PET/CT imaging and consolidate evidence from multiple studies to assess its prevalence, duration, and associations with vaccine-related factors and demographic characteristics.</p><p><strong>Method: </strong>Using multiple databases, a systematic review and meta-analysis was conducted on studies reporting RAL on FDG PET/CT following COVID-19 vaccination. The primary outcome was RAL prevalence, while the secondary outcomes were maximum standardized uptake value (SUVmax), vaccine-to-scan interval, and associations with vaccine type and demographics.</p><p><strong>Results: </strong>A total of 25 studies comprising of 5010 subjects were included. Mean SUVmax of reactive nodes was 2.8 ± 1.2. Overall, RAL prevalence was 38.6% ± 17.6, higher in females (58.1% versus 41.9%, P = 0.02) and younger individuals (mean age 63.3 versus 70.7 years, P = 0.03). The RAL rate was not statistically different between mRNA (39.9% ± 16.9) and non-mRNA vaccines (26.3% ± 30.9). However, subanalysis showed about 40% RAL with Pfizer and Moderna mRNA vaccines and AstraZeneca non-mRNA vaccine, versus much lower, below 20%, RAL with Sinovac and Johnson & Johnson non-mRNA vaccines. Stricter PET/CT interpretation criteria using blood pool threshold reduced RAL prevalence to <20%. RAL rate declined with time but was still present after 1 month.</p><p><strong>Conclusion: </strong>Low activity RAL is common on FDG PET/CT after COVID-19 vaccination, while higher activity RAL (above blood pool) that can lead to clinical errors is less frequent. The frequency of RAL is affected by expected factors, such as age, gender, vaccine type, and time after vaccination, which indirectly suggest the link between RAL and COVID-19 postvaccinal immunity.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144963848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automatic Lugano staging for risk stratification in lymphoma: a multicenter PET radiomics and machine learning study with survival analysis.","authors":"Setareh Hasanabadi, Seyed Mahmud Reza Aghamiri, Ahmad Ali Abin, Maryam Cheraghi, Mehrdad Bakhshayesh Karam, Habibeh Vosoughi, Farshad Emami, Hossein Arabi","doi":"10.1097/MNM.0000000000002046","DOIUrl":"10.1097/MNM.0000000000002046","url":null,"abstract":"<p><strong>Background: </strong>Lymphoma staging plays a pivotal role in treatment planning and prognosis. Yet, it still relies on manual interpretation of PET/computed tomography (CT) images, which is time-consuming, subjective, and prone to variability. This study introduces a novel radiomics-based machine learning model for automated lymphoma staging to improve diagnostic accuracy and streamline clinical workflow.</p><p><strong>Methods: </strong>Imaging data from 241 patients with histologically confirmed lymphoma were retrospectively analyzed. Radiomics features were extracted from segmented lymph nodes and extranodal lesions using PET/CT. Three machine learning classifiers (Logistic Regression, Random Forest, and XGBoost) were trained to distinguish between early-stage (I-II) and advanced-stage (III-IV) lymphoma. Model performance was evaluated using area under the curve (AUC), sensitivity, specificity, and accuracy together with survival analysis.</p><p><strong>Results: </strong>Among the three models evaluated, the logistic regression model incorporating both nodal and extranodal radiomic features performed the best, achieving an AUC of 0.87 and a sensitivity of 0.88 in the external validation cohort. Including extranodal features significantly improved classification accuracy compared to nodal-only models (AUC: 0.87 vs. 0.75). Survival analysis revealed advanced-stage patients had a fourfold higher mortality risk (hazard ratio: 0.22-0.26, P = 0.0036) and a median survival of 84 months. Key radiomic features, such as tumor shape irregularity and heterogeneity, were strongly associated with staging, aligning with Lugano criteria for extranodal spread.</p><p><strong>Conclusion: </strong>This study demonstrated the potential of PET radiomics features for automated Lugano staging. Adding extranodal features significantly improved staging accuracy and informed treatment.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144963944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18 F-FAPI PET/CT in chronic liver disease: myocardial fibroblast activation and its correlates.","authors":"Yangyang Wang, Guangjie Yang, Wenlong Yan, Wenji Yu, Ben Li, Lei Yan, Ju Zhang, Xin Wang, Yuan Zhuang, Zhenguang Wang, Yuetao Wang","doi":"10.1097/MNM.0000000000002002","DOIUrl":"10.1097/MNM.0000000000002002","url":null,"abstract":"<p><strong>Objectives: </strong>This study investigated the relationship between cardiac fibroblast activation and clinical parameters, electrophysiological findings, serum fibrosis markers, and hepatic fibroblast activation in patients with chronic liver disease.</p><p><strong>Methods: </strong>In this prospective study conducted from December 2021 to April 2022, 46 patients with chronic liver disease underwent fluorine-18 ( 18 F)-labeled fibroblast activation protein inhibitor (FAPI) PET/computed tomography (CT) imaging and 12-lead electrocardiogram (ECG). Abnormal cardiac 18 F-FAPI uptake was defined as uptake greater than that of the blood pool.</p><p><strong>Results: </strong>Among 46 patients with chronic liver disease analyzed, 14 showed positive myocardial FAPI uptake and 32 were negative. Significant differences were observed between positive and negative myocardial 18 F-FAPI PET/CT imaging groups in terms of age ( P  = 0.006), epicardial fat volume (EFV) ( P  = 0.004), Cornell voltage QRS amplitude ( P  = 0.022), and QRS duration ( P  = 0.032). The multivariable logistic regression analysis demonstrated a significant association between EFV [odds ratio (OR) = 1.019; P  = 0.024] and age (OR = 1.162; P  = 0.019) and positive myocardial FAPI uptake. Myocardial maximum target-to-background ratio (TBR max ) was positively correlated with hepatic TBR max ( r  = 0.405; P  = 0.005) and hepatic TBR mean ( r  = 0.412, P  = 0.004). Moreover, myocardial maximum standardized uptake value was positively correlated with serum laminin levels ( r  = 0.367; P  = 0.042).</p><p><strong>Conclusions: </strong>In patients with chronic liver disease, FAPI PET/CT imaging observed cardiac fibroblast activation, which was associated with electrophysiological parameters, hepatic FAPI uptake, and serum liver fibrosis markers. These findings suggest that 18 F-FAPI PET/CT imaging may offer a noninvasive approach for identifying early myocardial changes in chronic liver disease.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"824-834"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The current status and promising potential of copper-based radiopharmaceutical development towards future theranostics: an overview.","authors":"Parth Baberwal, Sunita Sonavane, Sandip Basu","doi":"10.1097/MNM.0000000000002011","DOIUrl":"10.1097/MNM.0000000000002011","url":null,"abstract":"<p><p>Copper is a naturally abundant element that has primarily five clinically important radioisotopes that can be used for theranostic applications in nuclear medicine ( 60 Cu, 61 Cu, 62 Cu, 64 Cu, and 67 Cu). With similar chemical properties which enable the synthesis of radiopharmaceuticals with similar pharmacokinetic properties, these isotopes of copper have different decay characteristics making them valuable for diagnostic or therapeutic purposes. 60 Cu, 61 Cu, 62 Cu, and 64 Cu have been used for diagnostic purposes owing to their β + decay and relatively short half-lives and 67 Cu has been employed for therapeutic uses because of its β - decay. This review covers the fundamental properties of copper, the production methods for the five significant copper radionuclides of interest in nuclear medicine, provides a summary of the available bifunctional chelators and the advantages and disadvantages of various copper radiopharmaceuticals employed in clinical and research settings. Finally, it discusses the clinical studies and explores the future potentials of these promising advancements in clinical practice.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"781-792"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144326409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors influencing lung shunt fraction on 99m Tc-MAA SPECT/computed tomography imaging in patients with hepatic malignancies for yttrium-90 microspheres embolization.","authors":"Xinyu Wang, Lei Zhang, Ruijie Du, Jiacheng Liu","doi":"10.1097/MNM.0000000000002010","DOIUrl":"10.1097/MNM.0000000000002010","url":null,"abstract":"<p><strong>Objective: </strong>To explore tumor characteristics and prior liver treatment associated with lung shunt fraction (LSF) during technetium-99 m ( 99m Tc)-macroaggregated albumin (MAA) imaging for patients with hepatic malignancies who are to undergo yttrium-90 radioembolization.</p><p><strong>Methods: </strong>Patients with hepatic malignancies who underwent transarterial 99m Tc-MAA single photon emission computed tomography/computed tomography (CT) imaging by consulting 90 Y microspheres for treatment from September 2021 to February 2025 at the Vascular and Interventional Surgery Department of Zhongda Hospital Southeast University were collected. All patients underwent contrast-enhanced CT or MRI for evaluation before hepatic angiography.</p><p><strong>Results: </strong>Of these 113 patients, with a median age of 60 years, were enrolled in this study. In the high LSF group, the tumor volume ( P = 0.001), perfusion volume ( P = 0.040), and 100INR ( P < 0.001) were significantly higher in these patients than in the other groups; for these patients, serum albumin was significantly lower than that in the other two groups ( P < 0.001). There was a significant difference in LSF between the hepatic vein (HV) groups; the highest LSF was found in such patients with clear evidence of tumor thrombus in the HV (median LSF = 26.50%), which was significantly higher than that in the group with HV invasion and the normal group (respectively, median LSF = 14.08 and 6.55%, P = 0.001); whereas, portal vein did not have any effect on the LSF level ( P = 0.445).</p><p><strong>Conclusion: </strong>Tumor data, liver function indexes, and specific treatment history are associated with higher LSF and indicate the need for interventions to reduce it.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"801-808"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prednisone-aided gross thyroid remnant ablation using 5.55 GBq of radioiodine in patients with differentiated thyroid cancer.","authors":"Junyao Wang, Ke Zhang, Ziyan He, Hong Chai, Jiahuan Yang, Peng Zhong, Zequan Chen, Libo Chen","doi":"10.1097/MNM.0000000000002006","DOIUrl":"10.1097/MNM.0000000000002006","url":null,"abstract":"<p><strong>Background: </strong>Radioiodine ( 131 I) remnant ablation (RRA) with activities ranging from 1.1-3.7 GBq showed dismal efficacy but a dose-effect relationship in patients with differentiated thyroid cancer (DTC) after less-than-total thyroidectomy.</p><p><strong>Methods: </strong>A prospective study was conducted in patients with DTC with gross thyroid remnants. All subjects received an activity of 5.55 GBq of 131 I in combination with a 1-week course of prednisone at a dose of 60 mg/day. The primary endpoints included success rate and safety; secondary endpoints included changes in 131 I uptake value, gross thyroid remnant volume, serum thyroglobulin levels, and levothyroxine replacement dose.</p><p><strong>Results: </strong>Forty-two patients were eligible for analyses with a median follow-up of 35 months. The ablation success rate reached 95.2%, with all grade 1 adverse events. The incidence of long-term (11.9%) adverse events was significantly lower than intermediate (28.6%) and immediate (69.0%) ones. The most frequent treatment-related immediate adverse events included neck pain (54.8%), weakness (30.1%), neck swelling (23.8%), stomachache (21.4%), palpitation (16.7%), and nausea (9.5%). After RRA, the median 24-h 131 I uptake value and the thyroid remnant volume decreased significantly ( P  < 0.05). The thyrotropin-stimulated thyroglobulin level dropped remarkably (20.54 ± 21.58 vs. 1.54 ± 3.21 mIU/L; P  < 0.05), becoming undetectable in 11 (28.9%) patients; While the dose of administered levothyroxine enhanced notably ( P  = 0.033).</p><p><strong>Conclusion: </strong>Our data demonstrated that prednisone-aided RRA utilizing a single dose of 5.55 GBq of 131 I achieved a high success rate of 95.2% and an excellent safety profile in patients with DTC with gross thyroid remnant.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"793-800"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting clinical outcomes using 18F-FDG PET/CT-based radiomic features and machine learning algorithms in patients with esophageal cancer.","authors":"Gozde Mutevelizade, Nazim Aydin, Ozge Duran Can, Orkun Teke, Ahmet Furkan Suner, Merve Erdugan, Elvan Sayit","doi":"10.1097/MNM.0000000000002003","DOIUrl":"10.1097/MNM.0000000000002003","url":null,"abstract":"<p><strong>Objective: </strong>This study evaluated the relationship between 18F-fluorodeoxyglucose PET/computed tomography (18F-FDG PET/CT) radiomic features and clinical parameters, including tumor localization, histopathological subtype, lymph node metastasis, mortality, and treatment response, in esophageal cancer (EC) patients undergoing chemoradiotherapy and the predictive performance of various machine learning (ML) models.</p><p><strong>Methods: </strong>In this retrospective study, 39 patients with EC who underwent pretreatment 18F-FDG PET/CT and received concurrent chemoradiotherapy were analyzed. Texture features were extracted using LIFEx software. Logistic regression, Naive Bayes, random forest, extreme gradient boosting (XGB), and support vector machine classifiers were applied to predict clinical outcomes. Cox regression and Kaplan-Meier analyses were used to evaluate overall survival (OS), and the accuracy of ML algorithms was quantified using the area under the receiver operating characteristic curve.</p><p><strong>Results: </strong>Radiomic features showed significant associations with several clinical parameters. Lymph node metastasis, tumor localization, and treatment response emerged as predictors of OS. Among the ML models, XGB demonstrated the most consistent and highest predictive performance across clinical outcomes.</p><p><strong>Conclusion: </strong>Radiomic features extracted from 18F-FDG PET/CT, when combined with ML approaches, may aid in predicting treatment response and clinical outcomes in EC. Radiomic features demonstrated value in assessing tumor heterogeneity; however, clinical parameters retained a stronger prognostic value for OS.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"835-847"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive factors for the efficacy of radioiodine therapy in patients with Graves' disease.","authors":"Haruna Iwanaga, Naotoshi Fujita, Shinji Abe, Rintaro Ito, Yumi Abe, Ryogo Minamimoto, Ryuichi Nishii, Shinji Naganawa, Katsuhiko Kato","doi":"10.1097/MNM.0000000000002045","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002045","url":null,"abstract":"<p><strong>Objective: </strong>The primary treatments for Graves' disease include antithyroid drugs (ATD), thyroidectomy, and iodine-131 (I-131) therapy. This study aimed to identify factors predicting treatment outcomes and the treatment period required to achieve euthyroidism after I-131 administration.</p><p><strong>Methods: </strong>This study included 109 patients with Graves' disease who underwent I-131 therapy. Patients achieving euthyroidism or hypothyroidism within 1 year were classified as the success group, whereas those with remaining hyperthyroidism were classified as the failure group. Thyroid volume, computed tomography (CT) values, 24-h radioiodine uptake, effective half-life, the levels of free triiodothyronine, free thyroxine, thyroid-stimulating hormone, and thyrotropin receptor antibody, history of I-131 therapy, history of ATD use, history of potassium iodide use, and thyroid absorbed dose were analysed.</p><p><strong>Results: </strong>Larger thyroid volume [odds ratio = 0.982, 95% confidence interval (CI): 0.967-0.998, P < 0.05] was identified as a predictive factor for treatment failure, as determined by multivariable logistic regression. In contrast, a shorter treatment period was associated with lower thyroid volume (hazard ratio = 0.990, 95% CI: 0.982-0.999, P < 0.05), higher thyroid absorbed dose (hazard ratio = 1.007, 95% CI: 1.002-1.011, P < 0.01), and lower thyroid CT values (hazard ratio = 0.963, 95% CI: 0.939-0.987, P < 0.01), as identified by multivariable Cox regression.</p><p><strong>Conclusion: </strong>Larger thyroid volume was associated with treatment failure. Smaller thyroid volume, higher thyroid absorbed dose, and lower thyroid CT values were significant predictors of the treatment period required to achieve euthyroidism after I-131 administration.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144963942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}